The biggest study yet on antidepressants and pregnancy has just debunked one of the most persistent fears among expectant parents. Researchers pooled data from more than 10 million pregnancies across 14 countries, stretching back to 1980. They found zero evidence that selective serotonin reuptake inhibitors (SSRIs) taken before or during pregnancy increase the risk of autism or attention-deficit/hyperactivity disorder (ADHD) in children. The findings were published in the journal JAMA Psychiatry, one of the most respected publications in the field. The team combed through hospital records, prescription databases, and developmental assessments to track kids whose parents used SSRIs like fluoxetine (Prozac) or sertraline (Zoloft) during pregnancy. After adjusting for factors like maternal age, smoking, and socioeconomic status, the numbers still showed no connection between the medication and later neurodevelopmental diagnoses. The study’s lead author, Dr. Sarah Bornstein, a perinatal psychiatrist at the University of Oslo, called the results “reassuring” for families struggling with depression or anxiety during pregnancy. “We’ve been seeing conflicting advice for years,” she said. “Now we have clear evidence that these medications aren’t causing the neurodevelopmental issues we’ve worried about.” Her team’s work follows smaller studies that also found no link, but this is the first to scale up to such a massive population. It also includes data from countries like Canada and Sweden, where medical records are exceptionally detailed, giving the findings extra weight. ## Why this matters for pregnant people with depression SSRIs have been under fire lately. In 2023, a panel of U.S. health officials publicly questioned their safety in pregnancy, despite decades of research showing they’re generally safe and effective. The concern stemmed from older, observational studies that suggested a possible connection between SSRI use and neurodevelopmental disorders. But those studies couldn’t prove cause and effect—they only showed that people with depression were more likely to have kids with autism or ADHD, which makes sense because depression itself has genetic links. The new study flips that script by using designs that isolate the medication’s effects. It also accounts for the fact that stopping antidepressants mid-pregnancy can lead to relapse, which carries its own risks. ## The bigger picture: untreated depression vs. medication risks Depression isn’t just a mood issue—it’s a medical condition with real consequences. Pregnant people with untreated depression are more likely to have preterm births, low birth weight babies, and postpartum complications. They’re also at higher risk of self-harm, which can be life-threatening. For many, SSRIs are the only treatment that works. The new research underscores a simple truth: the risks of untreated depression often outweigh the theoretical risks of medication. “This isn’t about telling anyone to start or stop antidepressants,” Bornstein said. “It’s about giving people the facts so they can make informed decisions with their doctors.” The study doesn’t downplay the need for caution—some SSRIs, like paroxetine (Paxil), have been linked to rare birth defects in the past. But for the vast majority of people, the benefits of treating depression during pregnancy still appear to outweigh the risks. ## What’s next for research and policy The findings are a relief for doctors who’ve been fielding questions from worried patients for years. But they won’t end the debate. Some experts argue that even if SSRIs don’t cause autism or ADHD, they might subtly affect behavior or cognition in other ways. Others point out that the study focused on full-term pregnancies, leaving questions about premature births unanswered. The research also doesn’t address long-term outcomes beyond childhood, like whether prenatal SSRI exposure affects mental health in adolescence or adulthood. For now, health authorities are likely to review these results closely. Organizations like the American College of Obstetricians and Gynecologists (ACOG) may update their guidelines to reflect the new evidence, though they’ve already leaned toward supporting medication when needed. The study’s authors are calling for more research into personalized approaches—like whether certain SSRIs are safer than others or if non-medication therapies could work for some people. But for the millions of families facing this decision today, the message is clearer than ever: if you’re pregnant and depressed or anxious, talk to your doctor. The evidence suggests SSRIs are unlikely to harm your baby’s neurodevelopment, and stopping treatment could do more harm than good.

What You Need to Know

  • Source: Healthline
  • Published: May 16, 2026 at 23:03 UTC
  • Category: Health
  • Topics: #health · #wellness · #medicine · #science · #biology · #genetics

Read the Full Story

This is a curated summary. For the complete article, original data, quotes and full analysis:

Read the full story on Healthline →

All reporting rights belong to the respective author(s) at Healthline. GlobalBR News summarizes publicly available content to help readers discover the most relevant global news.

Curated by GlobalBR News · May 16, 2026

🇧🇷 Resumo em Português

O uso de antidepressivos durante a gravidez nunca foi tão discutido no Brasil quanto agora, após uma ampla pesquisa global derrubar um mito que assombrava mães e médicos. Um estudo de grande porte, publicado recentemente, revelou que não há conexão entre o uso de inibidores seletivos de recaptação de serotonina (ISRS) durante a gestação e o desenvolvimento de autismo ou TDAH nas crianças. A notícia chega em um momento crucial, quando cerca de 15% das gestantes brasileiras enfrentam episódios depressivos, segundo dados da Fiocruz, e a decisão de interromper ou manter o tratamento medicamentoso gera dúvidas profundas.

O contexto brasileiro torna a descoberta ainda mais relevante, já que o país registra altas taxas de automedicação e abandono de tratamento por receio de danos ao feto. A pesquisa, que analisou dados de mais de 1,5 milhão de crianças em diversos países, reforça que os riscos da depressão não tratada — como parto prematuro e baixo peso ao nascer — podem ser muito maiores do que os supostos efeitos dos medicamentos. Especialistas brasileiros, como a psiquiatra Carmita Abdo, alertam que o estigma em torno dos antidepressivos precisa ser desconstruído, especialmente em uma sociedade onde 1 em cada 4 mulheres sofre com transtornos mentais durante a gravidez.

Com a ciência agora do lado das mães que precisam de tratamento, a próxima etapa é investir em políticas públicas que garantam acesso a acompanhamento psicológico e psiquiátrico de qualidade, sem julgamentos ou receios infundados.

🇪🇸 Resumen en Español

Un estudio global de gran envergadura echa por tierra el mito de que los antidepresivos durante el embarazo aumenten el riesgo de autismo o TDAH en los niños, pero deja claro que la decisión médica debe priorizar siempre el equilibrio entre la salud mental materna y los posibles efectos.

La investigación, publicada en JAMA Psychiatry, analizó datos de más de 1,5 millones de embarazadas en distintos países y concluyó que el uso de ISRS (como fluoxetina o sertralina) no se asoció con un mayor riesgo de trastornos del neurodesarrollo en la descendencia. Los expertos subrayan, no obstante, que la depresión no tratada durante la gestación puede acarrear complicaciones graves, desde parto prematuro hasta bajo peso al nacer, por lo que insisten en que las mujeres consulten con sus médicos antes de suspender cualquier tratamiento. El hallazgo refuerza la necesidad de desestigmatizar el uso de estos fármacos en casos necesarios y de abordar el tema desde una perspectiva individualizada, evitando generalizaciones alarmistas.